{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055649","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.291607+00:00","generated_at":"2026-06-02T12:27:16.253646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MindMed reports Q1 net loss $54.4M; MM120 GAD trial hits key endpoint, FDA Breakthrough Therapy","bullets":["Net loss $54.4M Q1'24 (vs $24.8M); includes $27.7M warrant fair value change. R&D $11.7M, G&A $10.5M.","Cash $252.3M at Mar 31 (vs $99.7M Dec'23). Expects funding into 2026.","Phase 2b MM120 GAD: 7.7-pt HAM-A improvement vs placebo (p<0.003), 65% response, 48% remission at Week 12.","FDA Breakthrough Therapy for MM120 in GAD. Phase 3 initiation planned H2 2024.","CFO Schond Greenway departed May 3. Executive search for new CFO underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055649","json":"https://secwatch.observer/filing/0000950170-24-055649.json","markdown":"https://secwatch.observer/filing/0000950170-24-055649.md","text":"https://secwatch.observer/filing/0000950170-24-055649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/0000950170-24-055649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/mnmd-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:27:16.253646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}